Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma()

Inhibition of the RAS-RAF-ERK-pathway using sorafenib as a first-line and regorafenib as a second-line treatment approach is the only effective therapeutic strategy for advanced hepatocellular carcinoma (HCC). Recent studies suggest that wild-type KRAS and HRAS isoforms could majorly contribute to H...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neoplasia
Main Authors: Dietrich, Peter, Gaza, Anne, Wormser, Laura, Fritz, Valerie, Hellerbrand, Claus, Bosserhoff, Anja Katrin
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2019
Assuntos:
Original article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6370713/
https://ncbi.nlm.nih.gov/pubmed/30685691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2018.11.011
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares